<PAGE>

              SECURITIES AND EXCHANGE COMMISSION
                    WASHINGTON, D.C.  20549

                          FORM 10-QSB

(Mark One)

[ X ]    QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE
         SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended                 MARCH 31, 1999           
                               -----------------------------------------

                                       OR

[    ]   TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT


                         Commission file number 0-19567

                              CARDIAC SCIENCE, INC.
     -------------------------------------------------------------------
       (Exact name of Small Business Issuer as specified in its charter)

             DELAWARE                                       33-0465681  
------------------------------------------------------------------------
     (State or other jurisdiction of                  (I.R.S. Employer
      incorporation or organization)                 Identification No.)

  1176 MAIN STREET, SUITE C, IRVINE, CALIFORNIA                92614
------------------------------------------------------------------------
  (Address of principal executive offices)

Issuer's telephone number, including area code:          (949)  587-0357


Check whether the issuer (1) filed all reports required to be filed by 
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for 
such shorter period that the registrant was required to file such reports), 
and (2) has been subject to such filing requirements for the past 90 days. 
Yes  X     No
   -----     -----

The number of shares of the Common Stock of the registrant outstanding as of 
May 7, 1999 was 7,888,332.

<PAGE>


                              CARDIAC SCIENCE, INC.

                              INDEX TO FORM 10-QSB

                          PART I. FINANCIAL INFORMATION
                          -----------------------------
<TABLE>
<CAPTION>
                                                                                       PAGE NO.
                                                                                       --------
<S>                                                                                       <C>
Item 1.     Financial Statements:

            Consolidated Condensed Balance Sheets as of March 31, 1999 (Unaudited)
              and December 31, 1998                                                        3

            Consolidated Condensed Statements of Operations (Unaudited) for the
              Three months ended March 31, 1999 and 1998                                   4

            Consolidated Condensed Statements of Cash Flows (Unaudited) for the
              Three months ended March 31, 1999 and 1998                                   5

            Consolidated Condensed Notes to Financial Statements (Unaudited)               6

Item 2.     Management's Discussion and Analysis or Plan of Operation                      9

                           PART II. OTHER INFORMATION
                           --------------------------

Item 1.     Legal Proceedings                                                             12

Item 2.     Changes in Securities and Use of Proceeds                                     12

Item 3.     Defaults Upon Senior Securities                                               12

Item 4.     Submission of Matters to a Vote of Security Holders                           12

Item 5.     Other Information                                                             12

Item 6.     Exhibits and Reports on Form 8-K                                              12

Signatures                                                                                13

</TABLE>

                                       2

<PAGE>


ITEM 1.  FINANCIAL STATEMENTS

                              CARDIAC SCIENCE, INC.

                      CONSOLIDATED CONDENSED BALANCE SHEETS
<TABLE>
<CAPTION>

                                                                                     (Unaudited)
                                                                                      March 31,             December 31,
                                                                                        1999                    1998
                                                                                  ------------------     ------------------
<S>                                                                              <C>                     <C>
                                     ASSETS

Current Assets:
  Cash and cash equivalents                                                        $        391,862      $        1,247,602
  Prepaid expenses                                                                           43,468                  30,129
                                                                                 -------------------     ------------------
                            Total current assets                                            435,331               1,277,731

Equipment, net                                                                              216,669                 117,710
Investment in unconsolidated affiliate                                                      111,000                 115,000
Other assets                                                                                 45,266                  45,266
                                                                                  ------------------     -------------------
                                                                                  $         808,265      $        1,555,707
                                                                                  ------------------     -------------------
                                                                                  ------------------     -------------------

                     LIABILITIES AND STOCKHOLDERS' (DEFICIT)
Current liabilities:
  Current portion of capital lease obligation                                     $          18,966      $            3,413
  Accounts payable and accrued expenses                                                   1,536,928               1,599,216
  Notes payable                                                                              93,749                 225,000
                                                                                  ------------------     -------------------
                            Total current liabilities                                     1,649,643               1,827,629
                                                                                  ------------------     -------------------
Long term portion of capital lease obligation                                                90,465                  16,001
                                                                                  ------------------     -------------------
Stockholders' (Deficit):
  Preferred Stock - $.001 par value; 1,000,000 shares authorized, none
   issued or outstanding                                                                       ---                     ---
 Common stock - $ 0.001 par value; 20,000,000 shares authorized, 7,138,332
  issued and outstanding at March 31, 1999 and 7,014,738 at                                                               
  December 31, 1998                                                                           7,138                   7,015
 Common stock subscribed                                                                    500,000                 100,000
 Additional paid-in capital                                                              10,937,567              10,823,448
 Accumulated deficit                                                                    (12,376,548)            (11,218,386)
                                                                                  ------------------     -------------------
                          Total stockholders' (deficit)                                    (931,843)               (287,923)
                                                                                  ------------------     -------------------
                                                                                  $         808,265        $      1,555,707
                                                                                  ------------------     -------------------
                                                                                  ------------------     -------------------
</TABLE>

    The accompanying notes are an integral part of the financial statements.

                                       3
<PAGE>


                              CARDIAC SCIENCE, INC.

                 CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS

                                   (Unaudited)
<TABLE>
<CAPTION>


                                                                                       Three Months
                                                                                           Ended
                                                                                      March 31, 1998
                                                             Three Months Ended        (Restated see
                                                                March 31, 1999            Note 5)
                                                             -------------------    -----------------
<S>                                                          <C>                    <C>
Operating expenses:
 Research and development                                     $         597,028      $       418,279
 Marketing                                                              275,249               50,051
 General and administrative                                             281,112              252,165
                                                             -------------------    -----------------
Loss from continuing operations                                      (1,153,389)            (720,495)
Interest expense, net                                                    (3,172)              (4,029)
                                                            --------------------    -----------------
Loss from continuing operations before provision                                    
 for income taxes                                                    (1,156,561)            (724,524)
Provision for income taxes                                                1,600                1,600
                                                             -------------------    ----------------
Net loss from continuing operations                                  (1,158,161)            (726,124)
Income from discontinued operations, net of                                         
  income taxes                                                              ---               14,618
                                                             -------------------    -----------------
Net loss                                                      $      (1,158,161)     $      (711,506)
                                                             -------------------    -----------------
                                                             -------------------    -----------------
Basic and diluted income (loss) per share:
  Continuing Operations                                       $           (0.16)     $         (0.15)
  Discontinued Operations                                                   ---                 0.01
                                                             -------------------    -----------------
Net income (loss) per share                                   $           (0.16)     $         (0.14)
                                                             -------------------    -----------------
                                                             -------------------    -----------------
Weighted average number of shares used in the                                       
 computation of net loss per share                                     7,072,360           4,984,560
                                                             -------------------    -----------------
                                                             -------------------    -----------------
</TABLE>


    The accompanying notes are an integral part of the financial statements.

                                       4
<PAGE>


                              CARDIAC SCIENCE, INC.

                 CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
                 -----------------------------------------------
                                   (Unaudited)
<TABLE>
<CAPTION>

                                                                                                   Three months ended
                                                                                  Three months        March 31,1998
                                                                                     ended         (Restated see Note
                                                                                 March 31,1999             5)
                                                                               ------------------- --------------------
<S>                                                                             <C>                <C>
Cash flows from operating activities:
Net loss                                                                        $      (1,158,161)  $         (711,506)
Adjustments to reconcile net loss to net
  cash used in operating activities from continuing operations:
    Income from discontinued operations                                                       ---              (14,618)
    Depreciation and amortization                                                          12,140                9,728
    Compensation related to fair value of options granted to non-                                  
       employees                                                                            4,700                  ---
    Expenses paid with common stock                                                        84,195               20,000
    Changes in operating assets and liabilities,exclusive of Diagnostic
      Monitoring:
    Prepaid expenses                                                                      (13,338)             (16,953)
    Accounts payable and accrued expenses                                                 (12,289)             156,611
                                                                                ------------------  -------------------
Net cash provided by operating activities from continuing operations                   (1,082,753)            (556,738)
                                                                                ------------------  -------------------
Net cash used in discontinued operations                                                      ---               15,665
                                                                                ------------------  -------------------
Cash flows from investing activities:
    Purchase of equipment                                                                 (36,635)              (2,868)
    Decrease in other assets                                                                4,000                  ---
                                                                                ------------------  -------------------
Net cash used by investing activities                                                     (32,635)              (2,868)
                                                                                ------------------  -------------------
Cash flows from financing activities:
    Payments on notes payable                                                            (131,252)             (13,928)
    Proceeds from line of credit                                                                               200,000
    Proceeds from note payable                                                                                 200,000
    Proceeds from common stock subscribed                                                 500,000                  ---
    Proceeds from exercise of common stock warrants                                           350                  ---
    Costs of equity issuances                                                            (109,450)             (20,987)
                                                                                ------------------  -------------------
Net cash provided by financing activities                                                 259,648              365,085
                                                                                ------------------  -------------------
Net decrease in cash and cash equivalents                                                (855,740)            (178,856)
Cash and cash equivalents at beginning of period                                        1,247,602              561,351
                                                                                ------------------  -------------------
Cash and cash equivalents at end of period                                      $         391,862   $          382,495
                                                                                ------------------  -------------------
                                                                                ------------------  -------------------
</TABLE>

     The accompanying notes are an integral part of the financial statements.

                                       5



<PAGE>


                              CARDIAC SCIENCE, INC.

        CONSOLIDATED CONDENSED NOTES TO FINANCIAL STATEMENTS (UNAUDITED)
                                 MARCH 31, 1999

1.   ORGANIZATION AND CAPITALIZATION OF THE COMPANY

     Cardiac Science, Inc. (the "Company") was incorporated on May 20, 1991 
to develop, manufacture and market software driven non-invasive 
(non-surgical) Automatic External Cardioverter Defibrillator ("AECD") devices 
(the "Products") to treat persons suffering from or at high risk of 
life-threatening arrhythmias. The Products, all of which are still under 
development, are designed to continuously monitor, quickly detect and then 
automatically, through transmission of electrical energy charges to the 
patient's heart, terminate the ventricular tachyarrhythmia (dangerously fast 
heart rate) and/or ventricular fibrillation (quivering of the heart following 
tachyarrhythmia, which usually results in death).

     On April 11, 1997, the Company acquired Innovative Physician Services, 
Inc. (d.b.a. Diagnostic Monitoring) ("DM"). The Company sold substantially 
all of the assets of Diagnostic Monitoring on December 31, 1998 (see notes 4 
and 5).

2.   CONTINUED EXISTENCE

     Additional capital is needed to fulfill the Company's current marketing, 
research and product development goals. Through March 31, 1999, the Company 
incurred losses of approximately $12.3 million. Recovery of the Company's 
assets is dependent upon future events, the outcome of which is 
indeterminable. Additionally, successful completion of the Company's 
development program and its transition to attain profitable operations is 
dependent upon achieving a level of revenues adequate to support the 
Company's cost structure. The Company anticipates that its current cash 
balance will be sufficient to meet the Company's cash requirements through 
June 30, 1999. Given the current applications of cash, the Company expects 
that additional capital will be necessary to sustain growth and viability. In 
this respect, the Company is considering a number of alternatives, including 
additional equity financings and corporate partnerships. There can be no 
assurance that any such transactions will be available at terms acceptable to 
the Company, if at all, or that any financing transaction will not be 
dilutive to current stockholders, or that the Company will have sufficient 
working capital to fund future operations. If the Company is not able to 
raise additional funds, it may be required to significantly curtail or cease 
its operating activities. The accompanying financial statements have been 
prepared assuming that the Company will continue as a going concern.

3.   SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

     In the opinion of the Company's management, the accompanying 
consolidated condensed unaudited financial statements include all adjustments 
(which consist only of normal recurring adjustments) necessary for a fair 
presentation of its financial position at March 31, 1999 and results of 
operations and cash flows for the periods presented. Although the Company 
believes that the disclosures in these financial statements are adequate to 
make the information presented not misleading, certain information and 
disclosures normally included in financial statements prepared in accordance 
with generally accepted accounting principles have been condensed or omitted 
and should be read in conjunction with the Company's audited financial 
statements 

                                       6
<PAGE>

included in the Company's 1998 Annual Report on Form 10-KSB. Results of 
operations for the three months ended March 31, 1999 are not necessarily 
indicative of results for the full year.

4.   INVESTMENT IN UNCONSOLIDATED AFFILIATE

     On December 31, 1998, the Company acquired a 7.7% voting interest in 
Biosensor as partial consideration for the sale of substantially all of the 
assets of DM. The Company accounts for this investment using the equity 
method of accounting in accordance with Accounting Principles Board Opinion 
No. 18.

5.   DISCONTINUED OPERATIONS

     On December 31, 1998, the Company completed the sale of substantially 
all of DM's assets to Biosensor, a Minnesota corporation, pursuant to an 
Agreement for Purchase and Sale of Assets dated December 31, 1998. The 
Company received, in consideration for the sale, 1,440,000 shares of common 
stock of Biosensor valued at $115,000. In addition, Biosensor assumed certain 
liabilities amounting to approximately $107,000.

     The Company has restated its prior financial statements to present the 
operating results of DM as a discontinued operation. Included in the income 
from discontinued operations is amortization of goodwill of $16,428. 
Operating results from discontinued operations are as follows:

<TABLE>
<CAPTION>

                                                          For the three months
                                                          ended March 31, 1998
                                                          --------------------
<S>                                                       <C>
Sales                                                              $   446,712
Cost of sales                                                          290,363
                                                              ----------------
Gross profit                                                           156,349
Operating expenses:
  Research and development                                               1,459
  Selling                                                               89,467
  General and administrative                                            50,005
                                                              ----------------
Income from discontinued operations                                     15,418
Interest income (expense), net                                             ---
                                                              ----------------
Income from discontinued operations before
  provision for income taxes                                            15,418
Provision for income taxes                                                 800
                                                              ----------------
Net income from discontinued operations                             $   14,618
                                                              ----------------
                                                              ----------------
</TABLE>



6.   PRIVATE PLACEMENTS

     On March 31, 1999, the Company completed a private placement of 250,000 
shares of common stock and three-year warrants to purchase 62,500 shares of 
common stock at $2.50 per share, for an aggregate purchase price of $500,000 
to a foreign investor in an offshore transaction pursuant to Regulation S 
promulgated under the Securities Act of 1933, as amended. In connection with 
the offering, the Company is obligated to pay a finder fee equal to ten 
percent of the gross proceeds of the sale, payable in cash or common stock.

     In April 1999 the Company completed a private placement of 500,000 
shares of common stock and three-year warrants to purchase 125,000 shares of 
common stock at $2.50 per share, for an aggregate purchase price of $1 
million to a foreign investor in an offshore transaction pursuant to 
Regulation S promulgated under the Securities Act of 1933, as amended. In 
connection with the offering, the Corporation is obligated to pay a finder 
fee equal to ten percent of the gross proceeds of the sale, payable in cash 
or common stock.

                                       7
<PAGE>

ITEM 2.     MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

GENERAL
-------

     The following discussion should be read in conjunction with the 
consolidated financial statements of the Company and notes thereto set forth 
elsewhere in this Quarterly Report on Form 10-QSB.

     The Company is engaged in the development of non-invasive 
fully-automatic external defibrillation ("AECD") devices (the "AECD 
Products") for the treatment of arrhythmias that lead to cardiac arrest. The 
Company commenced operations in May 1991. Until its acquisition of Diagnostic 
Monitoring in April 1997, its operations have consisted primarily of research 
and development activities and clinical FDA testing. Diagnostic Monitoring 
manufactured PC-based Holter Electrocardiogram ("ECG") systems and Ambulatory 
Holter recorders and distributed these products in over 40 countries. The 
Company sold substantially all of the assets of Diagnostic Monitoring on 
December 31, 1998 (see note 5 of the consolidated financial statements).

     Cardiac arrest is the single largest cause of death in the United States 
and Europe. The Company's mission is to increase the survival rate of cardiac 
arrest victims and create a new standard of care through the development and 
commercialization of its proprietary automatic defibrillation technology (the 
"AECD Technology").

     There are three AECD Products under development by Cardiac Science that 
utilize the AECD Technology. The Company's initial product, the Powerheart, 
is a bedside defibrillator-monitor designed for in-hospital use. The 
Powerheart attaches prophylactically to patients for the purpose of providing 
fully-automatic detection and treatment of life-threatening tachyarrhythmias 
(abnormal rhythms of the heart), such as ventricular tachycardia (dangerously 
rapid heart rate) and ventricular fibrillation (quivering of the heart), that 
lead to cardiac arrest. The second AECD Product under development, the 
RHYTHMx ECD module, is designed for integration into patient monitoring 
systems. Functionally, the RHYTHMx ECD module extends patient monitoring 
systems beyond diagnostics to provide patients with the added protection of 
automatic therapy delivery without human intervention. The third AECD Product 
under development is a fully-automatic public access defibrillator ("PAD") 
that can be used by first responders and other non-technical individuals 
outside of the hospital environment.

     The Company believes the AECD Products are ideally suited for 
hospitalized and non-hospitalized patients temporarily at risk (periods 
ranging from days to months) of suffering cardiac arrest. The Company has 
been issued one patent, has one additional patent under exclusive license and 
is in the process of filing additional patents relating to its AECD 
technology.

     RESULTS OF OPERATIONS
     ---------------------

     Research and development expenses increased to $597,028 from $418,279 
for the three months ended March 31, 1999 and 1998, respectively. This 
increase was due to engineering and pre-production costs associated with the 
commercialization of the Company's initial AECD(R) product, the Powerheart. 
Included in these costs were increases in personnel costs and related 
fringes, and costs associated with independent engineering contractors.

     Marketing expenses increased to $275,249 from $50,051 for the three 
months ended March 31, 1999 and 1998, respectively. The increase was a result 
of pre-marketing expenses related to the Powerheart 

                                       8
<PAGE>

including costs associated with the development of marketing literature and 
the addition of personnel and related fringes.

     General and administrative expenses increased to $281,112 from $252,165 
for the three months ended March 31, 1999 and 1998, respectively. Expenses 
which increased for the quarter ended March 31, 1999 as compared to the same 
quarter in 1998, included personnel costs and related fringes and 
professional fees.

     Interest expense, net, decreased to $3,172 from $4,029 for the three 
months ended March 31, 1999 and 1998, respectively, due to the declining 
balance of the note payable to a bank.

LIQUIDITY AND CAPITAL RESOURCES
-------------------------------

     At March 31, 1999, the Company had cash and cash equivalents of $391,862 
and a negative working capital of $(1,214,312) as compared to cash and cash 
equivalents of $1,247,602 and negative working capital of $(549,898) at 
December 31, 1998. From inception, the Company's sources of funding for 
operations were derived from equity placements aggregating approximately 
$11,700,000. The Company has incurred losses of approximately $12.3 million 
since inception and expects to incur substantial additional operating losses 
as a result of expenditures related to the marketing and sales support 
functions, research and product development activities and the initiation of 
clinical trials for future products. The timing and amounts of these 
expenditures will depend upon many factors, some of which are beyond the 
Company's control, such as the results of clinical trials, the requirements 
for and time required to obtain approval of 510(k) applications or other 
regulatory approvals, the progress of the Company's research and development 
programs, and market acceptance of the Company's products.

     The Company has raised $1,500,000 in a series of private placements through
the period ending April 30, 1999, $500,000 of which was received on March 31,
1999. In connection with these private placements the Company paid certain fees
and expenses. Additional capital will be needed to fulfill the Company's
marketing, research and product development goals. Successful completion of the
Company's development program for its AECD Products and its transition to attain
profitable operations is dependent upon achieving a level of revenues adequate
to support the Company's cost structure.

     The Company anticipates that its current cash balance will be sufficient to
meet the Company's cash requirements through June 30, 1999. Given the current
applications of cash, the Company expects that additional capital will be
necessary to sustain growth and viability. In this respect, the Company is
considering a number of alternatives, including additional equity financings and
corporate partnerships. There can be no assurance that any such transactions
will be available at terms acceptable to the Company, if at all, or that any
financing transaction will not be dilutive to current stockholders, or that the
Company will have sufficient working capital to fund future operations. If the
Company is not able to raise additional funds, it may be required to
significantly curtail or cease its operating activities. The accompanying
financial statements have been prepared assuming that the Company will continue
as a going concern.

YEAR 2000 ISSUE
---------------

     In the next nine months, many companies will face a potentially serious 
information systems (computer) problem because many software applications and 
operational programs written in the past may not properly recognize calendar 
dates beginning in the Year 2000. This problem could force computers to 
either shut down or provide incorrect information and could result in an 
inability to process transactions or engage in normal business activities. 
Based on a recent assessment, the Company believes that the software utilized 
by the Company will not be impacted by the Year 2000 issue. The Company 
believes that most of its existing 

                                       9
<PAGE>

information systems equipment, primarily composed of personal computers are 
Year 2000 compliant. The Company intends to replace those systems that are 
not compliant, the cost of which, is not anticipated to be material. In 
addition, the Company's initial products, the Powerheart, and its AECD 
Technology are not expected to encounter any problems with the Year 2000 
issue. The Company has initiated communications with its vendors regarding 
the Year 2000 Issue. Costs spent to date on the Year 2000 issue are minimal 
and the Company does not expect to incur additional costs which would be 
considered material. If the Company determines a particular vendor will be 
impacted by this problem, the Company may attempt to identify additional or 
replacement vendors, which could delay accessibility of the products and/or 
services provided by such vendors. Such a delay or failure to identify an 
additional or replacement vendor could have a material adverse effect on the 
Company's business, operating results and financial condition.

FORWARD LOOKING STATEMENTS
--------------------------

     Except for the historical information contained herein, the matters
discussed herein are forward looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. The forward looking statements
contained in this Quarterly Report on Form 10-QSB are subject to various risks,
uncertainties and other factors that could cause actual results to differ
materially from the results anticipated in such forward looking statements.
Included among the important risks, uncertainties and other factors are those
hereinafter discussed, the accuracy of which is necessarily subject to risks and
uncertainties.

     Few of the forward looking statements in this Quarterly Report on Form
10-QSB deal with matters that are within the unilateral control of the Company.
There is substantial regulation of the manufacture and sale of medical products,
including many of the Company's products, by governmental agencies in the United
States and foreign countries. These government agencies often have considerable
discretion in determining whether and when to approve the marketing of the
Company's products that have not yet received such approval.

     The availability of equity and debt financing to the Company is affected
by, among other things, domestic and world economic conditions and the
competition for funds. Potential investors and lenders will be influenced by
their evaluations of the Company and its products and comparisons with
alternative investment opportunities.

     Many of the Company's competitors have greater financial resources and
technical capabilities than the Company, which may enable such competitors to
design and produce superior products or to market their products in a manner
that achieves commercial success even in the face of technical superiority on
the part of the Company's products.

     The Company's patents may not offer effective protection against
competitors. Competitors may be able to design around the Company's patents or
employ technologies not covered by such patents. In addition, the Company's
patents may be challenged, and even if such patents are upheld, the diversion of
financial and human resources associated with patent litigation could adversely
affect the Company. The Company may be found to be violating the patents of
others and forced to obtain a license under such patents or modify the design of
its products.

     Rapid technological developments are expected to continue in the industries
in which the Company competes. The Company may not be able to develop,
manufacture and market products which meet changing user requirements or which
successfully anticipate or respond to technological changes in a cost-effective
and timely manner.

                                       10

<PAGE>


                              CARDIAC SCIENCE, INC.
                              ---------------------

                           PART II. OTHER INFORMATION

<TABLE>

<S>            <C>                
Item 1.         LEGAL PROCEEDINGS
                -----------------

                None.

Item 2.         CHANGES IN SECURITIES AND USE OF PROCEEDS
                ----------------------------------------- 

                On March 31, 1999, Cardiac Science, Inc. (the "Corporation")
                sold 250,000 shares of the Corporation's common stock, par value
                $0.001 per share (the "Common Stock"), and three-year warrants
                to purchase 62,500 shares of Common Stock at $2.50 per share,
                for an aggregate purchase price of $500,000, to a foreign
                investor in an offshore transaction pursuant to Regulation S
                promulgated under the Securities Act of 1933, as amended. In
                connection with the offering, the Corporation is obligated to
                pay a finder a fee equal to ten percent of the gross proceeds of
                the sale, payable in cash or Common Stock.

Item 3.         DEFAULTS UPON SENIOR SECURITIES
                -------------------------------

                None.

Item 4.         SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
                ---------------------------------------------------

                None.

Item 5.         OTHER INFORMATION
                -----------------

                None.

Item 6.         EXHIBITS AND REPORTS ON FORM 8-K
                --------------------------------

                a)   Exhibits:
                     27-Financial Data Schedule.

                b)   Reports on Form 8k - None.

</TABLE>

                                       11

<PAGE>



                                   SIGNATURES

     In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, hereunto duly
authorized.

                                                CARDIAC SCIENCE, INC.
                                                ---------------------

      Date: MAY 14, 1999                        /s/  BRETT L. SCOTT       
          --------------                       --------------------------
                                               Brett L. Scott
                                               Chief Financial Officer


                                       12

<PAGE>